Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure

作者：Prats Merche^*; Font Ramon; Garcia Ruiz Carmen; Cabre Carmen; Munoz Cortes Monica; Rosa Nogues M; Jariod Manel; Romeu Marta; Martinez Vea Alberto

来源：Nefrologia, 2013, 33(3): 355-361.

DOI：10.3265/Nefrologia.pre2013.Jan.11774

• Ferric carboxymaltose
• Chronic kidney disease
• Inflammation
• Adhesion molecules

Background: Treatment with parenteral iron causes oxidative stress, inflammation and endothelial dysfunction. Ferric carboxymaltose (FCM) is a new preparation of non-dextran iron which, due to its pharmacokinetics and stability, may induce less toxicity than other iron molecules. The aim of this study was to analyse the effect of FCM on inflammation and adhesion molecules in chronic kidney disease (CKD). Methods: Forty-seven patients with predialysis CKD and iron-deficiency anaemia received a single dose of FCM (15mg/kg, maximum dose 1 gram), At baseline and after 60 minutes (acute effect) and after 3 weeks and 3 months (sub-acute effect), we determined inflammatory markers: C-reactive protein (CRP), interleukin-6 (IL-6) and endothelial dysfunction: intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM). Results: Treatment with FCM was associated with a significant increase in haemoglobin levels: 10 (0,7) vs. 11,4 (1.3)g/dl, p<.0001. CRP, IL-6, ICAM and VCAM levels did not correlate with baseline haemoglobin or ferritin levels and there was no relationship between changes in these markers and those of haemoglobin after administration of FCM. No significant, acute or subacute changes occurred in any of the inflammatory or endothelial markers studied. Statin therapy was associated with lower VCAM concentrations. Conclusions: Treatment with high doses of FCM in patients with predialysis CKD has no proinflammatory effect and does not alter levels of adhesion molecules ICAM and VCAM in this population.

• 出版日期2013